Literature DB >> 15726618

Immunoreactive estrogen receptor in breast tumor and adjacent tissue: association with clinicopathological characteristics in Indian population.

Vijay L Kumar1, Anurag Srivastava, Rohit Singhal, Vijay Kumar.   

Abstract

BACKGROUND AND OBJECTIVES: Estrogen receptor (ER) status serves as an important prognostic marker in the management of breast cancer. The level of ER in breast tumor is different in different racial and ethnic groups. In the present study, we have compared the ER levels in breast tumor and adjacent normal tissue in Indian sub-population.
METHODS: Immunoreactive ER was measured by enzyme immunoassay in breast tumors (ERt) and adjacent area (ERa) derived from 45 breast cancer patients from North India. Clinical parameters like age, menopausal status, tumor stage, recurrence and treatment status were recorded.
RESULTS: A significant positive correlation was observed between the levels of ERt and ERa (r = 0.386, P = 0.009). While the ERt levels increased with advancing age (P = 0.087), the ERa levels did not change in different age groups. The ERt levels negatively correlated with tumor stage and recurrence (r = -0.263, P = 0.110 and r = -0.202, P = 0.189). A significant negative correlation was also observed between the ERa levels and tumor recurrence (r = -0.337, P = 0.025). Further, the ERt positivity was higher than the ERa positivity. The clinical characteristics like age, tumor stage, metastasis, recurrence, and treatment status did not correlate with ERt and ERa positivity.
CONCLUSIONS: The present study shows that the levels of ERt and ERa positively correlate and both ERt and ERa show negative correlation with tumor recurrence. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15726618     DOI: 10.1002/jso.20211

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  4 in total

1.  Breast cancer histology and receptor status characterization in Asian Indian and Pakistani women in the U.S.--a SEER analysis.

Authors:  Madhuri Kakarala; Laura Rozek; Michele Cote; Samadhi Liyanage; Dean E Brenner
Journal:  BMC Cancer       Date:  2010-05-11       Impact factor: 4.430

Review 2.  ERbeta in breast cancer--onlooker, passive player, or active protector?

Authors:  Emily M Fox; Rebecca J Davis; Margaret A Shupnik
Journal:  Steroids       Date:  2008-04-20       Impact factor: 2.668

3.  A Novel Subset of Triple-Negative Breast Cancers with Unique Histology and Immunohistochemical Expression.

Authors:  Swaminathan Kalyanasundaram; Shantaraman Kalyanaraman; Hidhaya Kaleelullah Fathima; Vidhya Mohan; Kavitha Selvaraj
Journal:  Iran J Pathol       Date:  2022-03-08

4.  Estrogen and progesterone receptor levels in nonneoplastic breast epithelium of breast cancer cases versus benign breast biopsy controls.

Authors:  Christy G Woolcott; Sandip K SenGupta; Wedad M Hanna; Kristan J Aronson
Journal:  BMC Cancer       Date:  2008-05-08       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.